Polyarteritis nodosa is a complex disease with a rich history, yet recent discoveries remind us that every disease provides opportunity for novel insights that may impact patient management and outcomes.
The investigation of mepolizumab has provided valuable information in EGPA not only in demonstrating therapeutic efficacy but also for the ability to conduct blinded, randomized trials in this rare and diverse disease.
The treatment of vasculitis has evolved significantly over the past 20 years, in some instances providing physicians and patients with a diverse range of options. With these options come questions of when to use these different therapies and how to weigh their risks and benefits.
This case study of recent dyspnea in a patient with granulomatosis with polyangiitis (Wegener’s) shows the value a multidisciplinary approach brings to vasculitis management.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Two highly distinct case vignettes demonstrate that multidisciplinary expertise is essential to managing the acute life-threatening complications that vasculitis can pose.
A new aortitis classification and discovery of a novel autoantigen’s role in aortitis are the latest insights to result from the intersection of high aortic surgery volumes with premier vasculitis expertise.
Despite advances in treating granulomatosis with polyangiitis (GPA), 50 to 70 percent of patients experience relapses after remission induction. Reduction of those relapses is a need that this study aims to meet.
A comprehensive suite of 30 free CME webcasts gives you the chance to see why clinicians came from 29 states and 20 nations to attend this year’s Biologic Therapies Summit VI.
Employing a low threshold for screening in vasculitis patients with signs or symptoms of venous thrombotic events can detect these important events that can be associated with morbidity and even mortality.
This daylong pre-symposium to Cleveland Clinic’s Biologic Therapies VI Summit is the most comprehensive live CME course to date on this complex vascular inflammatory disease.